Close

BIO Statement on China Approvals of Agricultural Biotechnology Products

Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement on the announcement that the People’s Republic of China’s National Biosafety Committee approved the final safety certificate for five agricultural biotechnology products.

New Report Shows Global Link Between Pro-Innovation Policies and Biotech Advances

Washington, D.C. (November 19, 2018) – A study released today highlights strategies, policies and best practices that have been successful in...

BIO Expands Cooperation with China-Based Pharma Group

Memorandum of Understanding for Cooperation continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts.

BIO’s Jim Greenwood Meets with India’s PM Modi

Delivers Message: India Must Protects Innovators’ Work Product

BIO Position on Proposals to Provide for Export Manufacturing Exemption during Patent Term Restoration

Export manufacturing exemptions weaken the IP protections afforded by Supplementary Protection Certificate and Patent Term Restoration.

Neat, Plausible, and Wrong

Why the focus on intellectual property fails to address the complexities of medicinal access in India Stephen M. Sammut and Daniel S. Levine Released in San Francisco, June, 2016 Supported by and prepared for the Biotechnology Innovation Organization and the Association of Biotechnology Led Enterprises The opinions expressed in this paper are those of the authors and do not necessarily reflect the opinions of BIO and ABLE.

BIO Statement Regarding the UN High Level Panel on Access to Medicines Report

Sadly the United Nations High Level Panel ignored the real issues that impact or delay delivery of innovative treatments and cures throughout the developing world, while focusing on policy recommendations in the one area – intellectual property – that would actually undermine ongoing research and development by hundreds of companies, universities and researchers.  

BIO Statement on USTR’s 2016 “Special 301 Report”

The Biotechnology Innovation Organization (BIO) released the following statement regarding The Office of the United States Trade Representative’s (USTR) 2016 Special 301 Report:

Eileen Yen, former Director, Sarawak Biodiversity Centre, Malaysia

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA